R. Lupinacci

发表

Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients

R. Betts, H. Teppler, A. Glasmacher, 2006, Cancer.

Comparison of caspofungin and amphotericin B for invasive candidiasis.

J. Perfect, R. Betts, J. Smietana, 2002, The New England journal of medicine.

A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis.

J. Smietana, E. Gotuzzo, N. Kartsonis, 2002, The American journal of medicine.

Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension.

C. Lines, R. Varma, J. Pigeon, 2012, American journal of ophthalmology.

A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants, children, and adolescents (PNEU-PLAN).

M. Rämet, P. Pitisuttithum, R. Dagan, 2022, Vaccine.

Paradoxical interpretations of noninferiority studies: violating the excluded middle

J. Eron, R. Lupinacci, M. Dinubile, 2012 .

Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic fever.

W. Gerth, J. Wingard, M. Berger, 2007, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma.

D. Schadendorf, S. Puig, P. Ascierto, 2019, European journal of cancer.

Global Distribution and Outcomes for Candida Species Causing Invasive Candidiasis: Results from an International Randomized Double-Blind Study of Caspofungin Versus Amphotericin B for the Treatment of Invasive Candidiasis

J. Perfect, M. Motyl, A. Colombo, 2003, European Journal of Clinical Microbiology and Infectious Diseases.

Response and relapse rates of candidal esophagitis in HIV-infected patients treated with caspofungin.

C. Sable, R. Lupinacci, M. Dinubile, 2002, AIDS research and human retroviruses.

A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED).

S. Koseoglu, R. Dagan, R. Rupp, 2023, Vaccine.

Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.

Thomas J Walsh, H. Teppler, T. Walsh, 2004, The New England journal of medicine.

Efficacy and safety of caspofungin therapy in elderly patients with proven or suspected invasive fungal infections

A. Meibohm, N. Kartsonis, C. Sable, 2008, European Journal of Clinical Microbiology & Infectious Diseases.

Caspofungin Use in Patients with Invasive Candidiasis Caused by Common Non-albicans Candida Species: Review of the Caspofungin Database

A. Colombo, N. Kartsonis, Arlene F Taylor, 2010, Antimicrobial Agents and Chemotherapy.

Sugammadex efficacy for reversal of rocuronium- and vecuronium-induced neuromuscular blockade: A pooled analysis of 26 studies.

M. Blobner, K. Khuenl-Brady, C. Assaid, 2017, Journal of clinical anesthesia.

Overview of safety experience with caspofungin in clinical trials conducted over the first 15 years: a brief report.

N. Kartsonis, R. Lupinacci, A. Ngai, 2011, International journal of antimicrobial agents.

A phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114, a 15-valent pneumococcal conjugate vaccine, and PCV13 with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION).

R. Dagan, R. Lupinacci, W. Phongsamart, 2022, Vaccine.

1184. A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13™ with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants (PNEU-DIRECTION)

R. Dagan, R. Lupinacci, W. Phongsamart, 2021, Open Forum Infectious Diseases.

Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in children with SCD: a V114-023 (PNEU-SICKLE) study

K. Feemster, R. Dagan, C. Quinn, 2022, Blood advances.

A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1).

F. Martinón-Torres, R. Dagan, L. Szenborn, 2023, Vaccine.

Safety, tolerability, and immunogenicity of V114 pneumococcal vaccine compared with PCV13 in a 2+1 regimen in healthy infants: A phase III study (PNEU-PED-EU-2).

M. Rämet, R. Dagan, P. Valentini, 2023, Vaccine.

336 A phase 3, multicenter, randomised, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of v114 in healthy infants (PNEU-PED)

S. Koseoglu, R. Dagan, R. Rupp, 2022, Abstracts.

1174. Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Catch-up Vaccination Regimens of V114 in Healthy Infants, Children, and Adolescents (PNEU–PLAN)

M. Rämet, P. Pitisuttithum, R. Dagan, 2021, Open Forum Infectious Diseases.

A phase 3 study of safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine, in children with HIV

S. Madhi, K. Feemster, R. Dagan, 2023 .

A phase 3 study of safety and immunogenicity of V114, a 15-valent PCV, followed by PPSV23, in children living with HIV.

S. Madhi, K. Feemster, R. Dagan, 2023, AIDS (London).

P534. Initial Assessment of the Clinical Profile of the PDE10A Inhibitor MK-8189 in Patients With an Acute Episode of Schizophrenia

S. Marder, R. Lupinacci, T. Voss, 2022, Biological Psychiatry.

Invasive candidiasis treated in the intensive care unit: observations from a randomized clinical trial.

N. Kartsonis, C. Sable, R. Lupinacci, 2007, Journal of critical care.

Efficacy and safety of caspofungin in obese patients.

N. Kartsonis, R. Lupinacci, D. Ryan, 2011, Medical mycology.

Sugammadex efficacy for reversal of rocuronium- and vecuronium-induced neuromuscular blockade: A pooled analysis of 26 studies.

M. Blobner, K. Khuenl-Brady, C. Assaid, 2017, Journal of clinical anesthesia.

Preservative‐free tafluprost in the treatment of open‐angle glaucoma or ocular hypertension in India: a phase III clinical trial

C. Baranak, R. Lupinacci, W. Herring, 2016, International journal of clinical practice.

Safety and Immunogenicity of V114 in Preterm Infants: A Pooled Analysis of Four Phase Three Studies

K. Feemster, T. Chapman, Shrita M. Patel, 2023, The Pediatric infectious disease journal.